Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic HER2-Positive Breast Cancer
Titel:
Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic HER2-Positive Breast Cancer
Auteur:
Wilks, Sharon Puhalla, Shannon O'Shaughnessy, Joyce Schwartzberg, Lee Berrak, Erhan Song, James Cox, David Vahdat, Linda